K. Graudenz

Most-cited papers

1. Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

   N. Shore, C. Zurth, R. Fricke, H. Gieschen +12 more

   2019Targeted oncology94 citations Open access

   Semantic Scholar

   Save

2. Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

   C. Zurth, M. Koskinen, R. Fricke, O. Prien +7 more

   2019European journal of drug metabolism and pharmacokinetics91 citations Open access

   Semantic Scholar

   Save

3. Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers.

   Steven C. R. Williams, N. Mazibuko, O. O'Daly, C. Zurth +5 more

   202010 citations

   Semantic Scholar

   Save

4. A phase I study to determine the effect of regorafenib (REG) on the pharmacokinetics (PK) of substrates of P-glycoprotein (P-gp; digoxin) and breast cancer resistant protein (BCRP; rosuvastatin) in patients with advanced solid tumors

   D. Strumberg, S. Al-Batran, I. Takács, L. Géczi +6 more

   20168 citations Open access

   Semantic Scholar

   Save

5. Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.

   C. Zurth, K. Graudenz, K. Denner, T. Korjamo +4 more

   2019Journal of Clinical Oncology6 citations

   Semantic Scholar

   Save

6. [From Einstein's Quantum Theory to modern laser therapy. The history of lasers in dermatology and aesthetic medicine].

   K. Graudenz, C. Raulin

   2003Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete6 citations

   Semantic Scholar

   Save

7. Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

   F. Marmé, C. Gomez-Roca, K. Graudenz, Fu-Nan Huang +4 more

   2018Cancer Chemotherapy and Pharmacology5 citations

   Semantic Scholar

   Save

8. [Diffused traumatic dirt and decorative tattooing. Removal by Q-switched lasers].

   K. Graudenz, B. Greve, C. Raulin

   2003Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete5 citations

   Semantic Scholar

   Save

9. Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)

   C. Zurth, K. Fizazi, R. Fricke, H. Gieschen +7 more

   2019Annals of Oncology3 citations Open access

   Semantic Scholar

   Save

10. Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

    A. Cleton, K. Graudenz, F. Huang, S. Fiala-Buskies +4 more

    20171 citations

    Semantic Scholar

    Save

11. Child-Pugh versus NCI-ODWG categorization for hepatic impairment studies - observations from a renal and hepatic impairment study with darolutamide, a novel investigational androgen receptor antagonist

    C. Zurth, Gary Wilkinson, Katrin Kettelhake, K. Graudenz +1 more

    20180 citations Open access

    Semantic Scholar

    Save

12. Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumors

    F. Marmé, C. Gomez-Roca, K. Graudenz, F. Huang +4 more

    20160 citations Open access

    Semantic Scholar

    Save